US Treasury Targets China Biotech as Investment Curbs Expand
Washington widens its Outbound Investment Security Program to biotech; Beijing warns of unspecified countermeasures.
The US Treasury just dropped a rule proposal that hits China where it hurts next: biotech. Thursday's expansion of the Outbound Investment Security Program already covered AI, quantum computing, hypersonics, and supercomputing. Now biotechnology — pushed hard by Treasury Secretary Scott Bessent — is on the list. The goal is simple: stop American money from building the technologies that could come back to threaten US national security.
Beijing fired back fast. China's commerce ministry called the move discriminatory, accused Washington of overreaching on national security grounds, and said it reserves the right to retaliate. No specifics. That vagueness is the real trade here — markets hate an unknown countermeasure, and Beijing knows it. The offshore yuan and China-exposed equities will stay jumpy until Beijing tips its hand.
Read more Post-Midterm Rally History Points to S&P 500 Gains Ahead →
For traders, the most exposed plays are obvious: Chinese biotech firms, US-listed ADRs tied to China tech, and the Hang Seng Tech index. Biotech is the freshest wound because cross-border funding in that sector runs deeper than in areas already under restriction. If rhetoric escalates during the public comment period — which could drag on for months — risk appetite toward anything China-facing takes the hit.
The timing isn't accidental. Days before the Treasury proposal, the State Department sanctioned five Chinese companies connected to former Google engineer Linwei Ding, convicted of stealing AI trade secrets. Beijing objected to that move too. The pattern is clear: Washington is tightening the technology perimeter on multiple fronts simultaneously, and China is running out of moves it hasn't already telegraphed.
The public comment period gives both sides room to negotiate and revise, but it also stretches uncertainty out. Months of headline risk with no resolution is not a favorable backdrop for long positions in Chinese tech or biotech. Stay nimble. Continue reading at Forexlive.
